• Blood Cancer Research Partnership

    Leadership and Investigators

    Rob Soiffer, MD
    CO-PI BCRP; Professor of Medicine Dana-Farber Cancer Institute, Harvard Medical School; Chief, Hematologic Malignancies

    Dr. Robert Soiffer 

    Dr. Soiffer graduated from New York University School of Medicine in 1983, and trained in internal medicine at Brigham and Women's Hospital, where he also was chief medical resident.

    He joined DFCI in 1988, after completing a medical oncology fellowship. He is currently chief of the Division of Hematologic Malignancies and co-director of the Adult Stem Cell Transplantation Program. He has served as vice president (2006), president (2007), and immediate past president (2008) of the American Society of Blood and Marrow Transplantation.


    Irene Ghobrial, MD
    CO-PI BCRP; Associate Professor of Medicine Dana-Farber Cancer Institute, Harvard Medical School

    Irene Ghobrial, MD 

    Dr. Ghobrial is an Associate Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. She is a physician Scientist who specializes in the field of Multiple Myeloma and Waldenstrom Macroglobulinemia.

    Her research interests are in the area of cell trafficking and cell metastasis in B cell malignancies and specific homing to the bone marrow niches. She is the principal investigator of several clinical trials in Multiple Myeloma and Waldenstrom Macroglobulinemia.


    Farah Daftary
    Director of Clinical Trial Operations at Dana-Farber Cancer Institute

    Farah is the Co-Director of the Clinical Trials Office at Dana-Farber Cancer Institute. She is well versed in clinical research, particularly in hematologic malignancies. Farah oversees the Clinical Research Managers in the Hematologic Malignancies Department.


    Rebecca Liguori, MS
    Research Project Manager II

    Rebecca Liguori 

    Rebecca is the dedicated Blood Cancer Research Partnership Project Manager. She has a Masters degree from the University of Colorado. She has 5 years work experience in Clinical Oncology Research in both the academic and CRO setting.


    Keting Chu, MD, PhD
    LLS VP, Therapy Acceleration Program

    Keting Chu, MD, PhD 

    Dr. Chu leads the TAP team for LLS. She is the Co-Founder, President and CEO of DigitAB, Inc., a startup company with a proprietary technology to revolutionize the proteomic research and medical diagnostics fields.

    She received her M.D. in Sun Yat-Sen Medical University in China, Ph.D. in microbiology and immunology at University of California at San Francisco (UCSF), and conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.


    Jun Xu, PhD
    LLS Director, Therapy Acceleration Program

    Jun Xu, PhD 

    Dr. Xu's roles include evaluating, selecting, and managing projects for TAP. She has more than fourteen years of experience at pharmaceutical and biotech industries. Dr. Xu led diverse oncology and immunology projects through progressing phases of drug discovery for over a decade at Wyeth/Pfizer.

    She received her Ph.D. from the University of California, San Diego, studying gene regulation by hormone receptors in Dr. Gordon Gill’s lab. Her Postdoctoral training was with Dr. Melvin Simon studying G protein signaling using animal models at the California Institute of Technology.


    Community Principal Investigators

    Asad Bashey, MD, PhD
    CO-PI BCRP; Professor of Medicine Dana-Farber Cancer Institute, Harvard Medical School; Chief, Hematologic Malignancies

    Asad Bashey, MD, PhD 

    Dr. Bashey is board certified in the subspecialties of medical oncology and hematology. He is the clinical research Medical Director for The Blood and Marrow Transplant Program at Northside Hospital. For 2013, Dr. Bashey has been selected as a Castle Connolly Top Doctor in the field of Hematology.

    Dr. Bashey's clinical and research interests include novel approaches to allogeneic bone marrow transplantation, strategies for augmentation of the graft-versus-tumor effect after allogeneic transplantation, and stem cell mobilization. He has received major funding from the National Institutes of Health for his clinical research. He currently serves as the Principal Investigator for The Blood and Marrow Transplant Program at Northside Hospital's Core Center status with the Bone Marrow Transplant Clinical Trials Network (BMTCTN).


    Charles Farber MD, PhD
    Hematology-Oncology Associates of Northern New Jersey

    Charles Farber MD, PhD 

    Dr. Farber attended the University of Rochester where he received his Bachelor's degree in Chemistry with High Distinction and Magna Cum Laude. He attended NYU where he received dual MD and PhD doctorates studying white blood cell biology.

    Dr. Farber is on the faculty of Memorial Sloan-Kettering Cancer Center on the Lymphoma Service. He is currently a Clinical Assistant Professor of Medicine at UMDNJ, Chair of the Hematologic Malignancy Panel at Carol G. Simon Cancer Center and the Secretary/Treasurer of the Oncology Society of New Jersey. He has expertise and has published 50 scientific papers in the areas of leukemias, lymphomas, white blood cell disorders and hematopoietic growth factors. He has been board-certified in Internal Medicine, Hematology & Medical Oncology.


    Jacquelyn Hedlund, MD
    Maine Center for Cancer Medicine

    Jacquelyn Hedlund, MD 

    Dr. Hedlund received her MS at Harvard School of Public Health and her MD at University of Vermont College of Medicine. She completed her Fellowship in Hematology at the University of Washington in Seattle and a Fellowship in Transfusion Medicine at the Puget Sound.

    Dr. Hedlund joined Maine Center for Cancer Medicine as a Physician Partner in 1998. Dr. Hedlund was the Medical Director of the Maine Medical Center Cancer Institute from 2007 – 2013. She is an active investigator on many clinical trials and is eager to increase the number of high quality research studies conducted at MCCM, as well as promote investigator-initiated translational studies that aim at advancing clinical applications from laboratory discoveries.


    Michael Martin, MD
    West Clinic

    Michael Martin, MD 

    Dr. Martin is Assistant Professor of Medicine at the University of Tennessee Health Science Center and a partner at the West Cancer Center where he is a medical oncologist. He also serves as the hematology and oncology site director for inpatient rotations at Methodist University Hospital and as a panel member on the National Comprehensive Cancer Network Acute Myeloid Leukemia guidelines.

    He chairs the University of Tennessee Hematology Oncology Fellowship Morbidity and Mortality conference and co-chairs the University of Tennessee joint surgical oncology – medical oncology conference series as well as serves as a preceptor for the University of Tennessee College of Pharmacy and Christian Brothers University Physician Assistant program. His research has focused on hematologic malignancies with a particular interest in Acute Myeloid Leukemia.


    Jeffrey Matous, MD
    Colorado Institute of Blood Cancer

    Jeffrey Matous, MD 

    Dr. Matous, specializes in the treatment of blood cancers such as multiple myeloma, amyloidosis, lymphoma and leukemia, as well as in the field of blood and marrow transplantation. Dr. Matous received his medical degree with honors from the University of Washington. He completed his internal medicine residency and chief residency at the University of Colorado Health Sciences Center. He is presently the medical director for the Colorado Blood Cancer Institute as well as a clinical professor of medicine at the University of Colorado Health Sciences Center. He is also on the board of the Leukemia-Lymphoma Society.

    Dr. Matous has a particular interest in medical education and supervises both medical students and internal medicine residents who are interested in the field of hematology/oncology. He has been recognized as an outstanding clinical teacher of the medicine housestaff. He is the lead investigator in clinical trials in the areas of lymphoma, Waldenstrom’s Macroglobulinemia, and multiple myeloma.


    Thomas Rado MD, PhD
    Columbia Basin Hematology Oncology

    Thomas Rado MD, PhD 

    Dr. Rado is an oncologist and hematologist. He completed his fellowship at Yale University and served 11 years as a Professor of Oncology at The University of Alabama and is currently a faculty member of the University of Washington Medical Center.

    Dr. Rado treats patients with a wide variety of solid tumors and hematological malignancies. He has developed particular expertise in treating patients with breast cancer, and collaborates closely with doctors at SCCA who share this special interest. He is the lead physician for the Clinical Research Department at CBHO, and Principal Investigator for several clinical trials. This activity makes new, and potentially valuable, drugs available to cancer patients in the Tri-Cities area through participation in clinical trials. Dr. Rado believes that caring for patients with cancer requires a combination of scientific knowledge and human empathy. He feels that the better we understand the biology of the tumor cell, the more likely we are to make wise recommendations regarding treatment.


    Craig Reynolds, MD
    Florida Cancer Affiliates/Ocala Oncology

    Craig Reynolds, MD 

    Dr. Reynolds lives in Ocala with his wife and three children. He gives frequent lectures. He likes to travel. He is active with youth groups in the community and spends quality time with his family. He is an avid bicyclist and is active in many community organizations.


    Laura Stampleman, MD
    Pacific Cancer Care

    Laura Stampleman, MD 

    Dr. Stampleman completed her undergraduate degree at The City College of the City University in New York, NY. She received her Medical Degree from Albert Einstein College of Medicine in New York, NY. She completed her residency at The Stamford Hospital in Stamford, CT and her Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center in New York, NY.

    Dr. Stampleman is the principal investigator for both Pacific Cancer Care and the ECOG CCOP of Salinas Valley memorial hospital. She served as the Medical Director of the ACOS certified program at Salinas Valley for 6 years and remains active in the cancer program with an emphasis on clinical trial enrollment and survivorship care. Dr. Stampleman lives with her husband in Aromas. They have two children and two grandchildren. In her spare time she enjoys hiking, gardening, baking, cooking and listening to music.


    Michaela Tsai, MD
    Virginia Piper Cancer Center at Abbott-Northwestern Hospital/Minnesota Oncology

    Michaela Tsai, MD 

    Dr. Tsai was called to a career in medicine at a young age. Studying both chemistry and religion in college, she came to appreciate the essential balance between the intellectual and the emotional, the scientific and the spiritual. Caring for patients with cancer allows her to put all of these elements into practice daily.

    As an oncologist, she continuously strives to seek new knowledge and to reexamine ideas of the past. Above all, the health and well being of her patients is her first concern. Dr. Tsai is married with two children. She loves travel, music and sports – swimming, soccer, hockey, and baseball. In her free time, she loves to read, cook, hike, bike, swim and run (and occasionally even win) half-marathons and marathons.


    Ira Zackon, MD
    New York Oncology Hematology

    Ira Zackon, MD 

    Dr. Zackon is the Director of the New York Oncology Hematology Stem Cell Transplant Program. He completed a professional development program in Autologous Stem Cell Transplantation and Hematologic Malignancies at the Dana-Farber Cancer Institute during 2011-12.

    In addition to further expanding his expertise in this specialized arena, he has enhanced the collaborative relationships with Dana-Farber specialists. Dr. Zackon most values family time with his wife and two children; he enjoys leisure sports and is an active community volunteer.

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms